Results 341 to 350 of about 413,339 (385)
Some of the next articles are maybe not open access.
Bulletin of Experimental Biology and Medicine, 2003
The combined cytostatic effect of doxorubicin and gestagens progesterone, medroxyprogesterone acetate, mecigestone, and butagest on doxorubicin-resistant and doxorubicin-sensitive human breast cancer MCF-7 cells was studied by the MTT assay. On the 6th day of incubation progesterone, medroxyprogesterone acetate, mecigestone, and butagest in high ...
P. V. Sergeev +11 more
openaire +2 more sources
The combined cytostatic effect of doxorubicin and gestagens progesterone, medroxyprogesterone acetate, mecigestone, and butagest on doxorubicin-resistant and doxorubicin-sensitive human breast cancer MCF-7 cells was studied by the MTT assay. On the 6th day of incubation progesterone, medroxyprogesterone acetate, mecigestone, and butagest in high ...
P. V. Sergeev +11 more
openaire +2 more sources
Effect of doxorubicin and 4′-epi-doxorubicin on mouse spermatogenesis
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 1986Flow cytometric and histological analysis, measurements of testicular weight and sperm head counts were performed to analyze the effects of doxorubicin (DX) and 4'-epi-doxorubicin (4'-epi-DX), two closely related antineoplastic agents, on mouse spermatogenesis. The DNA distribution patterns obtained by flow cytometry indicate the frequency of different
U. Hacker-Klom +2 more
openaire +3 more sources
Strategies to release doxorubicin from doxorubicin delivery vehicles
Journal of Drug Targeting, 2017Doxorubicin (DOX) is one of the most effective cytotoxic anticancer drugs and has been successfully applied in clinics to treat haematological malignancies and a broad range of solid tumours. However, the clinical applications of DOX have long been limited due to severe dose-dependent toxicities.
Chunwen Yue +6 more
openaire +3 more sources
Major obstacles to doxorubicin therapy: Cardiotoxicity and drug resistance
Journal of Oncology Pharmacy Practice, 2020Background Doxorubicin is one of the most commonly prescribed and time-tested anticancer drugs. Although being considered as a first line drug in different types of cancers, the two main obstacles to doxorubicin therapy are drug-induced cardiotoxicity ...
Hamdan S Al-malky +2 more
semanticscholar +1 more source
Comparative cytotoxicity of gold–doxorubicin and InP–doxorubicin conjugates
Nanotechnology, 2012Direct comparisons of different types of nanoparticles for drug delivery have seldom been performed. In this study we compare the physical properties and cellular activity of doxorubicin (Dox) conjugates to gold nanoparticles (Au) and InP quantum dots of comparable diameter.
Dekun Kong +3 more
openaire +3 more sources
Doxorubicin Degradation in Cardiomyocytes [PDF]
The Journal of Pharmacology and Experimental Therapeutics, 2007 Antitumor therapy with the anthracycline doxorubicin is limited by a severe cardiotoxicity, which seems to correlate with the cardiac levels of doxorubicin and its metabolization to reactive oxygen species. Previous biochemical studies showed that hydrogen peroxide-activated myoglobin caused an oxidative degradation of doxorubicin; however, a ...
Pierantonio Menna +2 more
openaire +2 more sources
DOXORUBICIN AND HYPERPIGMENTATION
Australian and New Zealand Journal of Surgery, 1982Sixty‐four patients with advanced malignant disease underwent treatment with Doxorubicin alone or in combination with other drugs. Twenty‐one percent developed hyperpigmentation. Four patients were noted to have total body pigmentation, a side effect which has not been recorded before.
G. B. Ong, T. T. Alagaratnam, T. K. Choi
openaire +3 more sources
Zur Pharmakokinetik von Doxorubicin*
Klinische Pädiatrie, 1986Doxorubicin serum levels were measured with a highly specific reversed-phase HPLC-method in patients undergoing combination chemotherapy. Serum elimination kinetics of doxorubicin follow a bi- or triphasic first order pattern with a high interpatient variability. T 1/2 of the first distribution phase was 5.4 min.
M. Grandt +4 more
openaire +3 more sources
Circumvention of doxorubicin-resistance in tumours by albumin-conjugated doxorubicin
European Journal of Cancer, 1995hormone sensitivity, where.as EGFR and pS2 appeared relatively isolated. Figure 2 confirms the variable clustering obtained by the PCA. This study shows the strong correlation between tumour size, node invasion and vascular emboli, and a clear separation between this group of factors and all other biological factors, including nuclear grade.
M. Volm, E.W. Pommerenke, H. Sinn
openaire +3 more sources
Bioconjugate Chemistry, 2012
We demonstrate the conjugation of the cancer drug doxorubicin (DOX) to poly(methacryloyloxyethyl phosphorylcholine) (polyMPC), linked by hydrazone groups, using (1) a one-pot ATRP/click sequence, and (2) a post-polymerization conjugation strategy.
Xiangji Chen +4 more
openaire +3 more sources
We demonstrate the conjugation of the cancer drug doxorubicin (DOX) to poly(methacryloyloxyethyl phosphorylcholine) (polyMPC), linked by hydrazone groups, using (1) a one-pot ATRP/click sequence, and (2) a post-polymerization conjugation strategy.
Xiangji Chen +4 more
openaire +3 more sources